Update (April 1, 2020): The US Food and Drug Administration is requesting that manufacturers pull all prescription and over-the-counter ranitidine drugs, known by the brand name Zantac, from the market immediately.

Cohen Milstein is investigating reports of cancer diagnosis related to the use of Zantac or generic versions of the drug ranitidine as a part of a consumer class action lawsuit it has filed against Pfizer Pharmaceuticals for making false and misleading claims about the safety of the drug.

If you believe that you or a loved one developed cancer as a result of taking Zantac/ranitidine and are interested in potentially participating in this investigation and/or potentially litigation, please complete the form below.

Cohen Milstein recognizes the importance of your privacy and personal data. Information provided in this survey is confidential and will not be shared/sold.

Millions of Americans take Zantac or generic versions of the drug ranitidine for treatment of heartburn and acid reflux. While drug makers marketed it as safe and effective, recent evidence suggests that the drug contains unsafe levels of N-Nitrosodimethylamine (NDMA), a substance classified as a probable human carcinogen by the Environmental Protection Agency, the World Health Organization, and the Occupational Safety and Health Administration.

Cancers that may be associated with taking Zantac/ranitidine include:

  • Bladder cancer
  • Colon cancer
  • Esophageal cancer
  • Kidney cancer
  • Liver cancer
  • Pancreatic cancer
  • Small intestine cancer
  • Stomach cancer
  • Testicular cancer
  • Uterine cancer

The following attorneys are overseeing the Zantac/ranitidine cancer investigation:

Theodore J. Leopold, Partner
T: 561-515-1400

Leslie M. Kroeger, Partner
T: 561-515-1400

Poorad Razavi, Of Counsel
T: 561-515-1400

Diana L. Martin, Of Counsel
T: 561-515-1400